Clinical Trials on Dental Caries Class II in Netherlands

Total 47 results

Medtronic Cardiac Rhythm and Heart Failure

Completed

Micra Transcatheter Pacing Study

Class I or II Indication for Implantation of a Single Chamber Ventricular Pacemaker According to ACC/AHA/HRS 2001 Guidelines and Any National Guidelines

United States, Netherlands, Japan, Serbia, Spain, Greece, Canada, India, Denmark, Czechia, South Africa, Malaysia, Austria, United Kingdom, Hungary, China, Australia, France, Italy
GH Research Ireland Limited

Recruiting

Phase 2 Clinical Trial of GH001 in Bipolar II Disorder

Bipolar II Disorder

Netherlands, Germany
Universidad El Bosque, Bogotá
King's College London; University of Leeds; University of Sheffield

Completed

Pandemic-adapted Caries Care Multicentre Single-group Interventional Study

Dental Caries in Children

Mexico, United Kingdom, Brazil, Peru, United States, Portugal, Argentina, Colombia, Dominican Republic, France, Netherlands, Russian Federation, Uruguay
Genzyme, a Sanofi Company

Completed

A Study of rhGAA in Patients With Late-Onset Pompe Disease

Pompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2

Netherlands
University Medical Center Groningen
Leiden University Medical Center

Not yet recruiting

The MuSt-PC: a Pilot Study to Assess Symptom Burden of Co-occuring Symptoms

Palliative Care

Netherlands
Radboud University Medical Center

Recruiting

MONITOR-IC: Determining and Improving Long-term Consequences of ICU Care (MONITOR-IC)

Post-Intensive Care Syndrome (PICS)

Netherlands
Maastricht University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development

Completed

Application of ATP Infusions in Palliative Home Care

Quality of Life | Cancer | Palliative Care | Survival

Netherlands
Erasmus Medical Center
Waterloo Foundation

Not yet recruiting

Online Brief CBT Intervention for Women With PCOS (How2deal)

Depression, Anxiety | Self Esteem | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Netherlands
Onze Lieve Vrouwe Gasthuis

Unknown

Influence of Light Therapy on Confusion in Patients at the Intensive Care Unit

Delirium | Intensive Care Unit Syndrome

Netherlands
Prof.dr Carin (C.C.D.) van der Rijt
Noordwest Ziekenhuisgroep; Rijnstate Hospital; Ikazia Hospital, Rotterdam; Laurens... and other collaborators

Recruiting

Appropriate Medication Use in Dutch Terminal Care (AMUSE)

Quality of Life | Palliative Care | Medication Therapy Management | Terminal Care | Clinical Decision Support System (CDSS)

Netherlands
Denali Therapeutics Inc.

Enrolling by invitation

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Mucopolysaccharidosis II

United States, Canada, Belgium, Czechia, Netherlands
Radboud University Medical Center
Jeroen Bosch Ziekenhuis

Recruiting

Improving Shared-Decision Making in the Intensive Care Unit Using Patient-reported Outcome Information

Patient Engagement | Intensive Care Unit Syndrome

Netherlands
Genzyme, a Sanofi Company

Completed

A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

Pompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2

United States, France, Netherlands
Genzyme, a Sanofi Company

Completed

Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.

Pompe Disease | Glycogen Storage Disease Type II (GSD II) | Acid Maltase Deficiency

United States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
Erasmus Medical Center

Recruiting

ACP in Older Patients With Multimorbidity: a Randomized Pilot

Quality of Life | Patient Satisfaction | Old Age; Debility | Multimorbidity | Patient Empowerment | Advance Care Planning | Health Economics

Netherlands
Medical Centre Leeuwarden
University Medical Center Groningen; University of Groningen

Recruiting

Improving Recovery After Critical Illness (IMPROVE)

Critical Illness | Muscle Weakness | Malnutrition | Post Intensive Care Unit Syndrome

Netherlands
Genzyme, a Sanofi Company

Completed

Late-Onset Treatment Study Extension Protocol

Glycogen Storage Disease Type II (GSD-II) | Pompe Disease (Late-Onset) | Glycogenesis Type II | Acid Maltase Deficiency (AMD)

United States, France, Canada, Netherlands, Australia
Genzyme, a Sanofi Company

Completed

Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa

Glycogenesis 2 Acid Maltase Deficiency | Pompe Disease (Late-Onset) | Glycogen Storage Disease Type II (GSD II)

United States, Netherlands, United Kingdom, Germany
Galina Velikova
The Leeds Teaching Hospitals NHS Trust; European Organisation for Research...

Completed

Long Term Implications of Rare Brain Tumours'

Quality of Life | Cognitive Impairment | Health-related Quality of Life | Long-term Effects of Cancer Treatment | WHO Grade II Oligodendroglial Tumor | WHO Grade III Oligodendroglial Tumor

Netherlands, United Kingdom
Amphia Hospital

Completed

Abdominal Aortic Aneurysm Patients Remain at Risk for Delirium on the Surgical Ward After Intensive Care Unit Dismissal

Delirium | Surgery | Surgery--Complications | Aortic Aneurysm, Abdominal | AAA | Intensive Care Unit Delirium

Netherlands
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Solid Tumors for Phase Ib | Pancreatic Cancer for Phase II | Colorectal Cancer for Phase II

United States, Canada, Australia, Belgium, Germany, Netherlands, Spain
Erasmus Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development

Terminated

Haloperidol for Delirium in Adult Critically Ill Patients (EuRIDICE)

Delirium | Critical Illness | Cognitive Impairment | Cognitive Decline | Intensive Care Psychosis

Netherlands
Radboud University Medical Center

Unknown

QUEST: QUality of Life and Experiences of Sarcoma Trajectories (QUEST)

Sarcoma | Quality of Life | Diagnostic Interval | Diagnostic Pathway | Care Needs

Netherlands, United Kingdom
Genzyme, a Sanofi Company

Completed

Avalglucosidase Alfa Extension Study (NEO-EXT)

Glycogen Storage Disease Type II Pompe Disease

United States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
Leiden University Medical Center
Comprehensive Cancer Centre The Netherlands; Dutch Cancer Society

Active, not recruiting

PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer (PORTEC-4a)

Endometrial Cancer Stage I | Endometrial Cancer Stage II

Netherlands, Germany, Belgium, France, Austria, Czechia, Ireland, Switzerland
Denali Therapeutics Inc.

Recruiting

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) (COMPASS)

Mucopolysaccharidosis II

United States, Spain, United Kingdom, Czechia, France, Canada, Italy, Belgium, Netherlands, Germany, Argentina, Sweden, Turkey, Brazil, Colombia
Genzyme, a Sanofi Company

Completed

A Prospective, Observational Study in Patients With Late-Onset Pompe Disease

Glycogen Storage Disease Type II

United States, France, Netherlands
Denali Therapeutics Inc.

Completed

A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

Mucopolysaccharidosis II

United Kingdom, United States, Italy, Netherlands
Denali Therapeutics Inc.

Active, not recruiting

A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

Mucopolysaccharidosis II

United States, Netherlands, Canada, United Kingdom
Sanofi

Completed

Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus (SAMS12)

Sleep Initiation and Maintenance Disorders

United States, France, Canada, Brazil, Russian Federation, Netherlands, Switzerland, Turkey, Malaysia, Taiwan, Czech Republic, Finland, Italy, Colombia, South Africa, Greece
Erasmus Medical Center

Completed

Resuscitation Outcomes in the Netherlands (ROUTiNE)

Quality of Life | Cognitive Impairment | Heart Arrest | Cardiac Arrest | Outcome, Fatal | Cardiac Arrest as A Complication of Care

Netherlands
Genzyme, a Sanofi Company

Completed

Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602

Glycogen Storage Disease Type II

United States, France, Germany, Israel, Italy, Netherlands, Taiwan
Genzyme, a Sanofi Company

Completed

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET)

Glycogen Storage Disease Type II;Pompe's Disease

Czechia, Taiwan, Belgium, Germany, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, Denmark, France, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Switzerland, Turk... and more
Fondazione IRCCS Istituto Nazionale dei Tumori,...
The Leeds Teaching Hospitals NHS Trust; University of Leeds; European Organisation... and other collaborators

Not yet recruiting

Validation of the European Oncology Quality of Life Toolkit

Cancer | Palliative Care | Survivorship

Hungary, Italy, France, United Kingdom, Netherlands, Estonia, Serbia, Lithuania, Slovenia, Albania, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Finland, Georgia, Germany, Greece, Ireland, Latvia, Moldova, Republic of, Norwa... and more
Sanofi

Recruiting

A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

Glycogen Storage Disease Type II

Belgium, United States, Italy, Spain, Taiwan, United Kingdom, Netherlands, France, Germany
Sanofi

Recruiting

Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa (Baby-COMET)

Glycogen Storage Disease Type II

Belgium, United States, China, Germany, Italy, Netherlands, Spain, Taiwan, United Kingdom
Amicus Therapeutics

Active, not recruiting

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

Pompe Disease

United States, Netherlands, United Kingdom, Australia, Germany, New Zealand
Hoffmann-La Roche
Association Française contre les Myopathies (AFM), Paris

Completed

Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.

Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type III Non Ambulant

Germany, Italy, France, Belgium, Poland, Netherlands, United Kingdom
BioMarin Pharmaceutical

Terminated

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

Late-onset Pompe Disease

United States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
Spark Therapeutics

Completed

Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease

Lysosomal Storage Diseases | Glycogen Storage Disease Type 2 | Pompe Disease (Late-onset) | Pompe Disease | LOPD | Acid Maltase Deficiency

United States, Italy, United Kingdom, Netherlands, France, Germany
Spark Therapeutics

Active, not recruiting

A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)

Lysosomal Storage Diseases | Glycogen Storage Disease Type II | Glycogen Storage Disease Type 2 | Pompe Disease (Late-onset) | Pompe Disease | LOPD | Acid Maltase Deficiency

United States, Canada, Netherlands, France, Denmark, Germany, Italy, United Kingdom
Amicus Therapeutics

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD

Pompe Disease (Late-onset)

United States, Germany, Taiwan, Belgium, Australia, Slovenia, Spain, Netherlands, Hungary, Japan, Austria, United Kingdom, France, Argentina, Canada, Sweden, Denmark, New Zealand, Greece, Korea, Republic of, Bosnia and Herzegovina, Ita... and more
Amicus Therapeutics

Completed

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease (PROPEL)

Pompe Disease (Late-onset)

United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more
Scholar Rock, Inc.

Active, not recruiting

Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab-ONYX (ONYX)

Neuromuscular Diseases | Neuromuscular Manifestations | Atrophy | Muscular Atrophy | Spinal Muscular Atrophy | Muscular Atrophy, Spinal | Spinal Muscular Atrophy Type 3 | SMA | Anti-myostatin | Spinal Muscular Atrophy Type II

United States, Spain, Belgium, Germany, Netherlands, Poland, Italy, France, United Kingdom
Genzyme, a Sanofi Company

Recruiting

Pompe Disease Registry Protocol

Glycogen Storage Disease Type II | Pompe Disease

Hungary, Croatia, Serbia, United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Denmark, France, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Japan, Jordan, Korea, Republic of, Kuwait and more
Hôpital Armand Trousseau

Completed

EUROpean Pain Audit In Neonates (EUROPAINsurvey)

Pain | Analgesia | Sedation | Intesive Care | Intratracheal Ventilation

Spain, United Kingdom, France, Norway, Finland, Germany, Portugal, Netherlands, Belgium, Italy, Sweden, Greece, Poland, Austria, Cyprus, Estonia, Lithuania, Malta
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Chordoma | Rhabdomyosarcoma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Metastatic Childhood Soft Tissue Sarcoma | Untreated Childhood Rhabdomyosarcoma | Stage I Adult Soft Tissue Sarcoma AJCC v7 and other conditions

United States, Netherlands, Canada, Australia, New Zealand, Puerto Rico, Switzerland

Clinical Trials on Dental Caries Class II in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations